Article citationsMore>>

Kobayashi, M., Farrar, J.L., Gierke, R., Britton, A., Childs, L., Leidner, A.J., et al. (2022) Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices—United States, 2022. Morbidity and Mortality Weekly Report, 71, 109-117.
https://doi.org/10.15585/mmwr.mm7104a1

has been cited by the following article:

• TITLE: The Evolution of Pneumococcal Vaccine and Vaccine Schedule in the USA: A Narrative Review of the Last Two Decades (2003-2023)

  AUTHORS: Queen L. Ekpa, Kelechukwu P. Oranu, Okelue E. Okobi, Omowunmi Adekoya

  KEYWORDS: Pneumococcal, Vaccines, PCVs, PPVs, Invasive Pneumococcal Diseases, S. pneumoniae, Evolution

  JOURNAL NAME: World Journal of Vaccines, Vol.15 No.1, February 13, 2025

  ABSTRACT: Streptococcus pneumoniae is a known notorious cause of invasive pneumococcal diseases as well as asymptomatic host carriage. Efforts have been made to curb this infectious organism through various vaccine strategies. However, its several strains and serotypes have necessitated various vaccine schedules and updates in the USA and globally. The evolution in pneumococcal vaccine schedules is not without challenges, such as cost, vaccine hesitancy, uptake and global disparities. This narrative review synopsizes the history of the Pneumococcal Vaccine and changes in its schedules in the last two decades based on published data. We focused on the impact of pneumococcal vaccination on invasive pneumococcal diseases, historical limitations, current challenges and future directions. Despite advancements in vaccination against S. pneumoniae infections, some pertinent issues exist that need to be swiftly fixed, to reduce national and thus global burden of pneumococcal diseases.